NCT05359341

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Comparative Study of DPP-4 Inhibitors and SGLT-2 Inhibitors in Egyptian Diabetic Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 175 (actual)
• Sponsor: Sadat City University · Academic / Other
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Our trial goal is to determine the efficacy and safety of sitagliptin in comparison with empagliflozin in type 2 diabetic Egyptian patients.

Conditions

• Diabete Type 2

Interventions

Type	Name	Description
DRUG	Sitagliptin 50 mg	Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
DRUG	Empagliflozin 12.5 MG	Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
DRUG	Sitagliptin 50 mg + Empagliflozin 12.5 MG	Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
DRUG	Empagliflozin 12.5 MG + Sitagliptin 50 mg	Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)

Timeline

• Start date: 2020-09-20
• Primary completion: 2021-09-20
• Completion: 2022-01-10
• First posted: 2022-05-03
• Last updated: 2022-05-03

Locations

1 site across 1 country: Egypt